In this episode, Radio Advisory is LIVE at Advisory Board’s 2022 Service Line Summit in St. Louis. Host Rachel Woods invites Advisory Board expert Fanta Cherif, Optum Rx senior director of pipeline and drug surveillance Bill Dreitlein, and Pear Therapeutics chief medical officer and head of development Dr. Yuri Marcich to have a gamified conversation about disruptive clinical products and how organizations can prepare for and embrace next-generation diagnostics and therapeutics.
- Q&A: Why a disruptive therapy is more consequential than an innovative one
- Disruptive therapeutics and diagnostics cheat sheets
- 3 disruptive behavioral health therapeutics—and what they mean for health equity
As we emerge from the global pandemic, healthcare is restructuring. What decisions should you be making, and what do you need to know to make them? Explore the state of the healthcare industry and its outlook for next year by visiting advisory.com/HealthCare2023.
Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.